ReviewJournal of clinical medicine2023
Comparable and Complimentary Modalities for Treatment of Small-Sized HCC: Surgical Resection, Radiofrequency Ablation, and Microwave Ablation.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Stereotactic body radiotherapy with CyberKnife for liver-confined hepatocellular carcinoma: systematic review and meta-analysis.Journal of radiation research · 2025Pooled it
- Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.World journal of surgical oncology · 2024Pooled it
- Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.Current oncology reports · 2026Review
- A bibliometric analysis of research trends and hotspots on recurrence after thermal ablation for hepatocellular carcinoma 2005-2025.Discover oncology · 2026Article
- Hepatectomy outperforms microwave ablation for colorectal cancer liver metastases, with anatomical location affecting ablation outcomes.Frontiers in surgery · 2026Article
- Current and Future Landscape of Hepatocellular Carcinoma Treatment.Oncology research · 2026Review
- Combining Microwave Ablation With CAR-T-Cell Therapy in Tumor-Bearing Mouse Models.Bio-protocol · 2025Article
- Competing risk analysis of surgical resectionTranslational cancer research · 2025Article
- Hypoxia-related signatures predicts survival, immunosuppression and PARP inhibitor resistance in HCC.Discover oncology · 2025Article
- Targeting Metabolism: Innovative Therapies for MASLD Unveiled.International journal of molecular sciences · 2025Review
- Microwave ablation vs. liver resection for patients with hepatocellular carcinomas.Journal of liver cancer · 2025Article
- Clinical study on ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma.American journal of translational research · 2025Article
- Development and validation of a nomogram to predict cancer-specific survival of patients with large hepatocellular carcinoma accepting surgical resection: a real-world analysis based on the SEER database.Journal of gastrointestinal oncology · 2024Article
- Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy.World journal of hepatology · 2024Review
- A Novel Nomogram to Predict Prognosis in Elderly Early-Stage Hepatocellular Carcinoma Patients After Ablation Therapy.Journal of hepatocellular carcinoma · 2024Article
- Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.Frontiers in oncology · 2024Article
- Hepatocellular Carcinoma from a Hepatologist's Perspective.Seminars in interventional radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the past decade, there has been continual improvement in both ablative and surgical technologies for the treatment of hepatocellular carcinoma (HCC). The efficacy of ablative therapy compared to surgical resection for HCC has not been thoroughly evaluated using multiple large-scale randomized controlled trials. By international consensus, if a patient is eligible, surgery is the primary curative treatment option, as it is believed to confer superior oncologic control.
objectiveto determine the efficacies of percutaneous ablative therapies and surgical resection (SR) in the treatment of HCC. Data sources, study appraisal, and synthesis methods: A meta-analysis using 5 online databases dating back to 1989 with more than 31,000 patients analyzing patient and tumor characteristics, median follow-up, overall survival, and complication rate was performed.
resultsAblative therapies are suitable alternatives to surgical resection in terms of survival and complication rates for comparable patient populations. For the entire length of the study from 1989-2019, radiofrequency ablation (RFA) produced the highest 5-year survival rates (59.6%), followed by microwave ablation (MWA) (50.7%) and surgical resection (SR) (49.9%). In the most recent era from 2006 to 2019, surgical resection has produced the highest 5-year survival rate of 72.8%, followed by RFA at 61.7% and MWA at 50.6%. Conclusions and key findings: Depending on the disease state and comorbidities of the patient, one modality may offer superior overall survival rates over the other available techniques. Interventional ablative methods and surgical resection should be used in conjunction for the successful treatment of small-sized HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.